Matrix Pharma regulatory update

MATX received a non-approvable letter from the FDA, which characterized as inadequate the information submitted by the company for AccuSite Injectable Gel for the treatment

Read the full 254 word article

How to gain access

Continue reading with a
two-week free trial.